BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Hepatol. Dec 27, 2025; 17(12): 110993
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.110993
Table 2 Treatment characteristics of the study group, n (%)
Treatment characteristics
Value (n = 30)
Dose fractionation
30 Gy/6 #1(3.3)
30 Gy/5 #4 (13.3)
50 Gy/5 #5 (16.7)
40 Gy/5 # 6 (20)
48 Gy/4 #1 (13.3)
35 Gy/5 #6 (20)
33 Gy/6 #1(3.3)
36 Gy/3 #3 (10)
48 Gy/6 #1(3.3)
45 Gy/5 #2 (6.7)
Treatment volumes
GTV diameter (median cm) (range)6.1 (2.54-10.63)
GTV volume (median cc) (range)49.05 (8.6-308)
PTV diameter (median cm) (range)7.9 (3.7-20.54)
PTV volume (median cc) (range)165.22 (27.3-453.6)
Serum AFP (prior to SBRT) (mean ± SD) (ng/mL)7181.14 ± 17948 P value = -0.049
Serum AFP (3 months after SBRT) (mean ± SD) (ng/mL)2183.44 ± 7323


Write to the Help Desk